In a June 12 press release, Nu-Med Plus Inc. (NUMD:OTC.MKTS) announced a strategic partnership with Millenium Biosciences to provide "company quality and regulatory service."
Nu-Med manufactures medical devices for delivery of inhaled nitric oxide in hospital and other settings. Inhaled nitric oxide "is presently used in neonate hypoxia therapy (inadequate oxygen level in newborns), COPD (chronic obstructive pulmonary disease) and other pulmonary problems and may have future applications for a variety of other diseases and medical complications that are currently being investigated," the company stated in the release.
Jeff Robins, president and CEO of Nu-Med Plus, praised Millennium and its leader, Mike D'Amico, in the release, stating, "For the past 30+ years, Mr. D'Amico has been a successful professional in the Quality and Regulatory field in the capacities of quality project management and regulatory affairs. We are excited to have retained Millennium Biosciences as we aggressively step forward pursuing ISO 13485 training and certification for our company along with approvals for our products."
Read what other experts are saying about:
Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
Disclosure:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Nu-Med Plus. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
